title: Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
abstract: Immunotherapies for various neurodegenerative diseases have recently emerged as a promising approach for clearing pathological protein conformers in these disorders. This type of treatment has not been assessed in models that develop neuronal tau aggregates as observed in frontotemporal dementia and Alzheimer's disease. Here, we present that active immunization with a phosphorylated tau epitope, in P301L tangle model mice, reduces aggregated tau in the brain and slows progression of the tangle-related behavioral phenotype. Females had more tau pathology than males but were also more receptive to the immunotherapy. The tau antibodies generated in these animals recognized pathological tau on brain sections. Performance on behavioral assays that require extensive motor coordination correlated with tau pathology in corresponding brain areas, and antibody levels against the immunogen correlated inversely with tau pathology. Interestingly, age-dependent autoantibodies that recognized recombinant tau protein but not the immunogen were detected in the P301L mice. To confirm that anti-tau antibodies could enter the brain and bind to pathological tau, FITC-tagged antibodies purified from a P301L mouse, with a high antibody titer against the immunogen, were injected into the carotid artery of P301L mice. These antibodies were subsequently detected within the brain and colocalized with PHF1 and MC1 antibodies that recognize pathological tau. Currently, no treatment is available for clearing tau aggregates. Our present findings may lead to a novel therapy targeting one of the major hallmarks of Alzheimer's disease and frontotemporal dementia.
authors: Department of Psychiatry, New York University School of Medicine, New York, New York 10016, USA.
authors: Ayodeji A
authors: AA
authors: Asuni
authors: Allal
authors: A
authors: Boutajangout
authors: David
authors: D
authors: Quartermain
authors: Einar M
authors: EM
authors: Sigurdsson
mesh_terms: D000367:Age Factors; D000704:Analysis of Variance; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D001522:Behavior, Animal; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D003704:Dementia / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007930:Leucine / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009447:Neuroblastoma; D011392:Proline / Q000235:genetics; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D021641:Recognition, Psychology / Q000187:drug effects / Q000502:physiology; D012737:Sex Factors; D016875:tau Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*
chemical_list: D000906:Antibodies; D016875:tau Proteins; D011392:Proline; D007930:Leucine
references: J Neurosci Res. 1999 Mar 15;55(6):713-23
references: 10220112
references: Exp Neurol. 1999 May;157(1):211-21
references: 10222124
references: Cell Mol Neurobiol. 2000 Apr;20(2):217-30
references: 10696511
references: J Neurosci. 2000 Apr 15;20(8):2926-33
references: 10751445
references: Nat Genet. 2000 Aug;25(4):402-5
references: 10932182
references: J Biol Chem. 2001 Jan 5;276(1):529-34
references: 11013246
references: Neurobiol Aging. 2000 Sep-Oct;21(5):719-27
references: 11016541
references: J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81
references: 11086195
references: FEBS Lett. 2001 Mar 23;493(1):40-4
references: 11278002
references: Am J Pathol. 2001 Aug;159(2):439-47
references: 11485902
references: Neurobiol Dis. 2001 Aug;8(4):555-67
references: 11493021
references: Science. 2001 Aug 24;293(5534):1487-91
references: 11520987
references: Science. 2001 Aug 24;293(5534):1491-5
references: 11520988
references: J Lab Clin Med. 1975 Nov;86(5):887-98
references: 1185045
references: J Neurosci Res. 2002 Jul 1;69(1):110-6
references: 12111822
references: Neurology. 2002 Aug 13;59(3):398-407
references: 12177374
references: Nat Rev Neurosci. 2002 Oct;3(10):824-8
references: 12360327
references: Peptides. 2002 Dec;23(12):2223-6
references: 12535702
references: Nat Med. 2003 Apr;9(4):448-52
references: 12640446
references: Magn Reson Med. 2003 Aug;50(2):293-302
references: 12876705
references: J Biol Chem. 1992 Jan 5;267(1):564-9
references: 1370450
references: FASEB J. 2004 Jan;18(1):182-4
references: 14630707
references: Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7252-6
references: 1496020
references: Brain Pathol. 2004 Jan;14(1):11-20
references: 14997933
references: Semin Cell Dev Biol. 2004 Feb;15(1):45-9
references: 15036206
references: Thromb Haemost. 2004 Jun;91(6):1056-64
references: 15175790
references: J Neurosci. 2004 Jul 14;24(28):6277-82
references: 15254082
references: Curr Drug Targets. 2004 Aug;5(6):495-502
references: 15270196
references: Neuron. 2004 Aug 5;43(3):321-32
references: 15294141
references: J Neurosci Methods. 2004 Sep 30;138(1-2):233-42
references: 15325132
references: J Pharmacol Exp Ther. 2005 Feb;312(2):659-68
references: 15375176
references: J Pharm Sci. 2004 Nov;93(11):2645-68
references: 15389672
references: J Biol Chem. 2005 Feb 4;280(5):3628-35
references: 15525637
references: Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):227-31
references: 15615853
references: Neurology. 2005 Jan 11;64(1):129-31
references: 15642916
references: Proc Natl Acad Sci U S A. 2005 May 10;102(19):6990-5
references: 15867159
references: J Neurosci. 2005 Jun 1;25(22):5446-54
references: 15930395
references: Neuron. 2005 Jun 16;46(6):857-68
references: 15953415
references: Curr Alzheimer Res. 2005 Apr;2(2):231-8
references: 15974923
references: Methods Mol Biol. 2005;299:299-308
references: 15980613
references: Science. 2005 Jul 15;309(5733):476-81
references: 16020737
references: Neurobiol Dis. 2005 Dec;20(3):814-22
references: 16125396
references: Am J Pathol. 2006 May;168(5):1598-607
references: 16651626
references: Curr Pharm Des. 2006;12(20):2569-85
references: 16842179
references: Exp Neurol. 1990 Mar;107(3):263-70
references: 1689666
references: Neurology. 1990 Mar;40(3 Pt 1):419-22
references: 1690363
references: Eur J Neurosci. 2006 Nov;24(9):2530-42
references: 17100841
references: Nat Cell Biol. 2007 Feb;9(2):139-48
references: 17187063
references: Neurobiol Aging. 2008 Jun;29(6):836-47
references: 17291630
references: J Biol Chem. 2007 Jun 29;282(26):18895-906
references: 17468102
references: J Biol Chem. 1990 Dec 5;265(34):21355-62
references: 2250029
references: Neurology. 1987 Nov;37(11):1780-4
references: 2444904
references: Acta Neuropathol. 1989;78(1):16-21
references: 2735186
references: J Neurol Sci. 1986 May;73(3):257-67
references: 3522806
references: Immunology. 1970 Jun;18(6):875-81
references: 4913804
references: J Neurosci Res. 1994 Dec 15;39(6):669-73
references: 7534834
references: Cell. 1995 Jul 28;82(2):331-40
references: 7543026
references: Neuroscience. 1994 Nov;63(1):95-122
references: 7898665
references: Prog Brain Res. 1994;101:383-90
references: 8029466
references: J Comp Neurol. 1994 Apr 22;342(4):481-96
references: 8040362
references: Neuroscience. 1993 Sep;56(1):109-27
references: 8232910
references: Exp Neurol. 1993 Apr;120(2):245-63
references: 8491281
references: J Neurosci Res. 1997 Apr 15;48(2):128-32
references: 9130141
references: J Neurosci. 1997 Aug 15;17(16):6142-51
references: 9236226
references: Neurobiol Aging. 1996 Nov-Dec;17(6):893-901
references: 9363801
references: Neurobiol Aging. 1997 Nov-Dec;18(6):591-608
references: 9461057
references: Brain Pathol. 1998 Apr;8(2):387-402
references: 9546295
references: Ann Neurol. 1998 Jun;43(6):815-25
references: 9629852
references: J Immunol. 1998 Jul 15;161(2):692-701
references: 9670944